Real-world analysis of GLP-1a drugs for weight loss finds low adherence and increased cost in first year

An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime), and Magellan Rx Management, (Magellan Rx), a Prime Therapeutics company, shows that 68 percent of individuals who newly started glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss were no longer taking the drug after one year. The data also show a substantial increase in health care cost in the first year among those who also started the drugs. Read the full article here.